Leritrelvir
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started May 20, 2022 (NCT05829551)
Timeline
Indications
Mechanism of action
- SARS-CoV-2INHIBITOR
SARS-CoV-2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06160622 | Phase 1 | Sep 26, 2023 | Guangdong Raynovent Biotech Co., Ltd |
| NCT06362460 | Phase 1 | Sep 18, 2023 | Guangdong Raynovent Biotech Co., Ltd |
| NCT06161259 | Phase 1 | Sep 14, 2023 | Guangdong Raynovent Biotech Co., Ltd |
| NCT06031454 | Phase 1 | Sep 1, 2023 | Guangdong Raynovent Biotech Co., Ltd |
| NCT06169085 | Phase 1 | Aug 24, 2023 | Guangdong Raynovent Biotech Co., Ltd |
| NCT05620160 | Phase 3 | Nov 12, 2022 | Guangdong Raynovent Biotech Co., Ltd |
| NCT05829551 | Phase 1 | May 20, 2022 | Guangdong Raynovent Biotech Co., Ltd |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangdong Raynovent Biotech Co., Ltd | For profit | 7 | 7 | 2 | 2022 |
1 organizations
Page 1 / 1